Amicogen Inc is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâ€™s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company sells its products in domestic and overseas markets.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/26/29	₩1,040.00	-6.73%	9,06,490
28/26/28	₩1,115.00	-2.28%	6,34,555
27/26/27	₩1,141.00	-0.87%	4,67,017
24/26/24	₩1,151.00	-6.65%	6,63,760
23/26/23	₩1,233.00	+5.38%	5,93,257

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 29/07/2026			5-day change	1st Jan Change
1,040.00 ^KRW	-6.73%		-11.11%	-41.64%

22/06	Amicogen, Inc. announced that it expects to receive KRW 9.9999989 billion in funding	CI
14/05	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	7.33TCr 5.05Cr 4.44Cr 4.14Cr 3.8Cr 7.12Cr 483.7Cr 7.29Cr 49Cr 19Cr 239.35Cr 19Cr 19Cr 827.45Cr	P/E 2024	-4.02x	P/E 2025	-3.28x
Enterprise Value	16TCr 11Cr 9.7Cr 9.05Cr 8.31Cr 16Cr 1.06TCr 16Cr 107.37Cr 42Cr 523.25Cr 41Cr 41Cr 1.81TCr	EV / Sales 2024	1.86x	EV / Sales 2025	4.43x
Free-Float	95.04%	Yield 2024 *	-	Yield 2025	-

22/06	Amicogen, Inc. announced that it expects to receive KRW 9.9999989 billion in funding	CI
14/05	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
14/11	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/25/22	Amicogen, Inc.(KOSDAQ:A092040) added to S&P Global BMI Index	CI
20/25/20	Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market	CI
14/25/14	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/25/12	Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.	CI
14/25/14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25/25/25	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
19/25/19	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/24/10	An undisclosed buyer agreed to acquire an unknown stake in Amicogen Biopharm Co., Ltd. from Amicogen, Inc. for KRW 54.7 billion.	CI
21/24/21	Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc..	CI

20/24/20	Bio-Works and Amicogen have concluded their technology transfer project.	AQ
10/21/10	Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works	AQ
17/21/17	Bio Works Technologies : Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea	AQ

Amicogen, Inc. Share Price

Stocks

A092040

KR7092040005

Biotechnology & Medical Research

Valuation: Amicogen, Inc.

Chart: Amicogen, Inc.

Latest news : Amicogen, Inc.

Press Releases: Amicogen, Inc.

News in other languages: Amicogen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Amicogen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-6.73%
1 week	-11.11%
Current month	-29.78%
1 month	-31.89%
3 months	-44.83%
6 months	-39.36%
Current year	-41.64%

1 week	1,010	1,233
1 month	1,010	1,513
Current year	1,010	2,300
1 year	1,010	4,400
3 years	1,010	9,400
5 years	1,010	20,625
10 years	1,010	24,825

Manager	Title	Age	Since
Jjeo Pyo CEO	Chief Executive Officer	53	-
Young-Chul Yoon PRN	Corporate Officer/Principal	55	28/03/2024
Chun-Gu Kim AUD	Comptroller/Controller/Auditor	69	27/03/2025

Director	Title	Age	Since
Jun-Ho Kim BRD	Director/Board Member	56	26/02/2025
Soon-Yong Kim BRD	Director/Board Member	58	26/02/2025
Young-Chul Yoon BRD	Director/Board Member	55	28/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03/03/26	Ji-Seong So	Buy	Director	435	0.0006%
03/03/26	Young-Chul Yoon	Buy	Director	109	0.0002%
27/02/26	Eun-seong Hwang	Buy		4,000	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICOGEN, INC.	-6.73%	-11.11%	-74.38%	-88.42%	5.05Cr
ARGENX SE	+0.47%	+2.27%	+50.78%	+70.84%	5.52TCr
WUXI APPTEC CO., LTD.	+2.83%	+0.48%	+28.18%	+82.59%	5.56TCr
BIONTECH SE	+0.54%	+1.22%	-16.62%	-13.47%	2.35TCr
INSMED INCORPORATED	-0.97%	-3.30%	-1.79%	+383.00%	2.24TCr
WUXI BIOLOGICS (CAYMAN) INC.	-5.08%	-4.74%	+11.92%	-15.24%	2.06TCr
GENMAB A/S	-2.15%	-2.30%	+27.27%	-31.03%	1.74TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-4.50%	-8.88%	+22.29%	+528.99%	1.52TCr
EXELIXIS, INC.	-2.09%	+0.64%	+49.78%	+178.74%	1.39TCr
PHARMAESSENTIA CORPORATION	-3.14%	-8.47%	+165.37%	+292.18%	1.37TCr
Average	-2.08%	-2.56%	+26.28%	+138.82%	2.38TCr
Weighted average by Cap.	-0.46%	-0.47%	+33.50%	+128.00%

	2024	2025
Net sales	17TCr 12Cr 11Cr 9.81Cr 9.01Cr 17Cr 1.15TCr 17Cr 116.37Cr 46Cr 567.11Cr 45Cr 44Cr 1.96TCr	4.2TCr 2.89Cr 2.54Cr 2.37Cr 2.18Cr 4.08Cr 277.14Cr 4.18Cr 28Cr 11Cr 137.14Cr 11Cr 11Cr 474.09Cr
Net income	-5.28TCr -3.64Cr -3.2Cr -2.98Cr -2.74Cr -5.13Cr -348.5Cr -5.25Cr -35Cr -14Cr -172.45Cr -14Cr -13Cr -596.16Cr	-3TCr -2.06Cr -1.81Cr -1.69Cr -1.55Cr -2.91Cr -197.78Cr -2.98Cr -20Cr -7.85Cr -98Cr -7.75Cr -7.58Cr -338.33Cr
Net Debt	11TCr 7.69Cr 6.75Cr 6.3Cr 5.79Cr 11Cr 736.18Cr 11Cr 75Cr 29Cr 364.29Cr 29Cr 28Cr 1.26TCr	8.69TCr 5.99Cr 5.26Cr 4.91Cr 4.51Cr 8.44Cr 573.72Cr 8.65Cr 58Cr 23Cr 283.9Cr 22Cr 22Cr 981.43Cr